(SEPTEMBER 15, 2022) Randall Holcombe, M.D., M.B.A., director of the UVM Cancer Center, spoke with WCAX-TV’s Darren Perron about President Biden’s “cancer moonshot” initiative, which aims to cut cancer fatalities by 50 percent in the next 50 years and direct federal resources to eventually find a cure.

Beginning in the fall, acupuncture will be provided at no cost to inpatient hematology and oncology patients at the University of Vermont (UVM) Medical Center, thanks to a new grant to the UVM Cancer Center from the Victoria Buffum Fund.

(JULY 11, 2022) Beth Zigmund, M.D., associate professor of radiology and director of lung cancer screening for UVMMC, explained the benefits of early detection and treatment as part of the UVM and Dartmouth cancer centers’ newly launched partnership with the state’s cancer coalition, NBC5 reported.

In a Journal of American Medical Association study, researchers - including UVM Professor and UVM Cancer Center member Brian Sprague, Ph.D. - found that 3D screening with digital breast tomosynthesis had certain benefits compared to breast cancer screening with conventional 2D digital mammography.

In a formal ceremony held at the University of Vermont’s Larner College of Medicine on June 28, 2022, Associate Professor of Surgery William Brundage, M.D., was invested as the inaugural Green and Gold Professor in the Division of Otolaryngology, Head and Neck Surgery.

Yvonne Janssen-Heininger, Ph.D., professor of pathology and laboratory medicine at the UVM Larner College of Medicine, is a 2022 recipient of the University Distinguished Professor Award. This title is a career appointment, and is the highest academic honor that UVM can bestow upon a member of the faculty.

(MARCH 20, 2022) Thomas Ahern, Ph.D., M.P.H., associate professor of surgical research and biochemistry, was lead author on a recent study on phthalates and cancer published in the "Journal of the National Cancer Institute," according to a Salon.com report.

In a first-of-its-kind study, research from the University of Vermont Cancer Center has linked phthalates, commonly called the “everywhere chemical,” to higher incidence of specific childhood cancers.

In recent years, total neoadjuvant treatment—a potent new therapy for advanced colorectal cancer—has emerged as the standard of care. But the treatment can be harsh, impacting quality of life for many patients. A new study published in Clinical Colorectal Cancer by a team of researchers affiliated with the University of Vermont Cancer Center highlights a variety of new colorectal cancer treatments that take into account both a patient’s likely health outcome and quality of life factors.

Frances Carr, Ph.D., professor of pharmacology at the Larner College of Medicine at the University of Vermont and UVM Cancer Center member, has been elected to the American Association for the Advancement of Science Fellows Class of 2021.